Indolent B-Cell Non-Hodgkin Lymphoma — Trials

Indolent B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 172
Recruiting: 85
Ph III recruiting: 4
Growth YoY: +34.6%
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 301–333 of 333 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00210392	VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy	terminated	Phase 2	12	International Extranodal Lymphoma Study Group (IELSG)OTHER	1	Mar 30, 2015	clinicaltrials
NCT00832234	Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia(BDR-WM)	completed	Phase 2	59	European Myeloma Network B.V.NETWORK	1	Feb 18, 2015